GV-971 for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 4 registered trials.

Why this status

  1. 20 Aug 2020: Trial registered, NCT04520412
  2. 27 Oct 2020: Trial started, NCT04520412
  3. 7 Dec 2021: Trial started, NCT05181475
  4. 6 Jan 2022: Trial registered, NCT05181475
  5. 18 Jun 2023: Trial registered, NCT05908695
  6. 31 Aug 2023: Trial started, NCT05908695

The trials

NCT04520412: A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease

State
Suspended
Phase
Phase 3
People
2,046 planned
Started
27 Oct 2020
Primary completion
Dec 2025
Arms
GV-971
Results
None posted
  1. 20 Aug 2020: Trial registered
  2. 27 Oct 2020: Trial started
  3. 23 Nov 2022: Trial suspended

NCT05181475: Long-term Efficacy and Safety Study of GV-971

State
Under way
Phase
Phase 4
People
800 taking part
Started
7 Dec 2021
Primary completion
Jan 2025
Arms
Sodium Oligomannate Capsules (GV-971)
Results
None posted
  1. 7 Dec 2021: Trial started
  2. 6 Jan 2022: Trial registered

NCT05430867: Efficacy and Safety of Memantine and Sodium Oligomannate in Patients With Moderate to Severe Alzheimer's Disease

State
State not given
Phase
Phase 4
People
150 planned
Started
1 Jul 2022
Primary completion
1 Jul 2024
Arms
GV-971 monotherapy group
Results
None posted
  1. 24 Jun 2022: Trial registered

NCT05908695: An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease

State
Under way
Phase
Phase 4
People
1,312 planned
Started
31 Aug 2023
Primary completion
Jun 2029
Arms
GV-971
Results
None posted
  1. 18 Jun 2023: Trial registered
  2. 31 Aug 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as GV-971 capsule, Sodium Oligomannate Capsules (GV-971).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.